Pacira BioSciences, Inc. (PCRX) |
| 21.6 -1.33 (-5.8%) 01-13 16:00 |
| Open: | 22.91 |
| High: | 22.95 |
| Low: | 21.535 |
| Volume: | 941,183 |
| Market Cap: | 983(M) |
| PE Ratio: | 45.96 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 27.16 |
| Resistance 1: | 25.01 |
| Pivot price: | 25.15 |
| Support 1: | 21.53 |
| Support 2: | 17.92 |
| 52w High: | 27.64 |
| 52w Low: | 19.84 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| EPS | 0.470 |
| Book Value | 16.920 |
| PEG Ratio | 0.00 |
| Gross Profit | 10.940 |
| Profit Margin (%) | 2.99 |
| Operating Margin (%) | 7.33 |
| Return on Assets (ttm) | 2.9 |
| Return on Equity (ttm) | 2.9 |
Tue, 13 Jan 2026
Opioid-sparing EXPAREL to reach patients in South Korea and Thailand - Stock Titan
Tue, 13 Jan 2026
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring a 29.59% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
Mon, 12 Jan 2026
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Zacks Investment Research
Mon, 12 Jan 2026
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt? - 富途牛牛
Fri, 09 Jan 2026
How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue - Yahoo Finance
Fri, 09 Jan 2026
What Analysts Are Saying About Pacira BioSciences Stock - Benzinga
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |